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Abstract 
The abnormal glucose tolerance of Type 2 diabetes is characterized by post-prandial 
hyperglycaemia. We aimed to examine whether the restoration of a more 
physiological insulin profile using rapid-acting insulin analogues might, through 
effects on glucose toxicity, improve endogenous insulin secretion rate (ISR) and 
secondly improve markers of vascular risk. Eighteen people with insulin-treated Type 
2 diabetes were recruited into a single centre, cross-over, open-labeled study. The 
order of pre-meal unmodified human insulin or insulin aspart was randomized: 
treatment periods lasted at least 8-12 weeks after which ISR was assessed by 
stepped low-dose glucose infusion and fasting markers of vascular risk measured. 
Glucose control was good (HbA1c 6.94 ± 0.12 (±SE) vs 7.07 ± 0.13 %, NS) with 
insulin aspart and human insulin. Mean post-prandial self-monitored blood glucose 
concentration was also good particularly with insulin aspart (7.5 ± 0.41 vs 8.19 ± 0.34 
mmol/l) but the difference did not reach statistical significance. Over 160 min ISR did 
not differ between insulin aspart and human insulin and there was also no change in 
various markers of vascular risk. In conclusion a meal-time+basal insulin regimen 
gave close to normal post-prandial blood glucose control with both the insulin aspart 
and human insulin regimens, such that no difference in ISR or markers of vascular 
risk could be demonstrated. 
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1. Introduction 
The earliest abnormality of glucose tolerance in the development of Type 2 diabetes 
is post-prandial hyperglycaemia. After an initial compensatory increase in pancreatic 
insulin secretion the developing β-cell failure results in impaired glucose tolerance 
characterized by post-prandial hyperglycaemia. With progressive β-cell failure, 
insulin secretion continues to diminish and overt diabetes develops [1]. The cause of 
this failure of the pancreas to produce insulin is not fully understood but a direct 
effect of glucose toxicity on the ability of the pancreatic β-cells to secrete insulin is 
thought to exacerbate the problem as glucose levels rise [2-4]. 
Restoration of a more physiological insulin profile resulting in a reduction in post-
prandial hyperglycaemia could, theoretically, reduce or reverse the toxic effect of 
raised blood glucose levels on the pancreatic β-cell. It is hypothesized that a 
reduction in post-prandial hyperglycaemia could, through effects on glucose toxicity, 
result in an improvement in endogenous insulin secretion in Type 2 diabetes. 
Rapid-acting insulin analogues have been consistently shown to reduce post-prandial 
blood glucose levels in both Type 1 [5-9] and Type 2 diabetes [10-13]. Therefore we 
aimed to examine whether the restoration of a more physiological insulin profile using 
insulin aspart could result in an improvement in endogenous insulin secretion when 
compared to unmodified human insulin in people with insulin-treated Type 2 
diabetes.  
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In this study endogenous insulin secretion was assessed using a low-dose stepped 
glucose infusion. The low-dose stepped glucose infusion has been shown to be a 
sensitive method of detecting small changes in insulin secretion [14,15]. This allowed 
comparison of endogenous insulin secretion rate in people with Type 2 diabetes 
using rapid-acting insulin analogue and human insulin treatment. 
A further aim of this study was to assess the effect of a reduction in levels of post-
prandial hyperglycaemia on a wide variety of metabolic and haemostatic parameters. 
We have previously found that a small reduction of 0.8 mmol/l in post-prandial blood 
glucose levels, which was achieved when insulin aspart was compared with human 
insulin as part of a double blind crossover study, does not have a significant effect on 
the levels of various metabolic parameters [16]. An open-label design was used since 
it was hoped that it might make target post-prandial blood glucose levels in the 
insulin analogue group easier to attain in order to achieve a larger difference in post-
prandial blood glucose levels between the two groups. In addition the length of each 
treatment period was increased from 6 weeks in our previous study to at least 8-12 
weeks. 
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2. Participants and methods 
2.1.Participants 
Eighteen insulin-treated people with Type 2 diabetes were recruited. Their 
clinical characteristics are given in Table 1. All patients gave written informed 
consent to participate in the study, which was carried out according to the 
principles of the Declaration of Helsinki and was approved by the local Ethics 
Committee. 
2.2 Methods 
A single centre, randomized, open-label, crossover design was used. 
Following recruitment participants were converted from their usual twice-daily 
insulin regimen to a pre-meal plus basal regimen using unmodified human 
insulin (Human Actrapid, Novo Nordisk, Bagsvaerd, Denmark) before each 
main meal and human NPH insulin (Insulatard, Novo Nordisk) before bed. All 
patients remained on this regimen for the run-in period lasting for a minimum 
of 1 week and a maximum time period of 4 weeks. A third party not involved in 
conducting the study randomized patients to either human soluble insulin or 
insulin aspart (NovoRapid, Novo Nordisk) before main meals for each 
treatment period. Patients remained on each pre-meal insulin for treatment 
periods lasting at least 8-12 weeks and at the end of each treatment period an 
in-patient study morning took place in order to assess insulin secretion and a 
fasting blood sample was taken for biochemical markers. Patients were then 
crossed-over to the second treatment arm, with the alternative pre-meal 
insulin and an identical study day took place at the end of the second 
treatment period. 
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Participants maintained a minimum of weekly contact with the investigator, 
when insulin doses were adjusted and were asked to carry out one seven-
point glucose profile per week. Target blood glucose levels were set as 4.0-
6.0 mmol/l pre-prandially and 5.0-7.5 mmol/l post-prandially in the absence of 
hypoglycaemia. 
Participants were instructed to inject pre-meal insulin subcutaneously 5 min 
before breakfast, lunch and dinner when injecting insulin aspart, and 30 min 
before meals when taking human soluble insulin. All participants remained on 
bed-time NPH and concomitant medication was continued throughout the 
study. 
At randomization and 1-2 weeks before each study morning pre-breakfast 
serum or plasma levels of the following metabolic and biochemical variables 
were measured: total cholesterol, HDL cholesterol, triglycerides, fibrinogen, 
plasminogen activator inhibitor-1 (PAI-1), and E-selectin. Albumin excretion 
rate was estimated using the results of three timed overnight urine collections. 
HbA1c was also measured at baseline and at the end of each treatment 
period. 
2.3 Study morning protocol  
Participants arrived at the Investigation Unit at 0800 h following a 12-h fast 
and having omitted their NPH insulin the previous evening. A sampling 
cannula was inserted into one forearm or hand vein and this forearm was 
maintained in a hand warming box for 15 min before any samples were taken 
and for the duration of the procedure in order to ensure arterialization of the 
venous sample. 
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At 0845 h (-15 min) a fasting blood sample was taken for plasma glucose 
estimation. Only patients with plasma glucose concentrations between 5.0 
and 9.0 mmol/l at 0845 h continued the study morning. In addition, on the 
second study morning plasma glucose level at 0845 h was no greater than 2.5 
mmol/l different from the first study morning. Participants whose plasma 
glucose levels did not meet these criteria were asked to return another day. 
At 0900 h a baseline blood sample was taken for plasma glucose and plasma 
C-peptide levels. A stepped low-dose glucose infusion (20% dextrose) was 
commenced at 0900 h. The stepped low-dose glucose infusion is based on a 
previously described method [14,15]. Glucose was infused at 2.0 mg/kg/min 
and maintained for 40 min, increasing to 4.0, 6.0 and 8.0 mg/kg/min, each 
step for 40 min. After commencing the glucose infusion blood samples were 
taken for plasma glucose and C-peptide at 10 min intervals for the first 20 min 
of each 40-min period and thereafter at 5 min intervals. 
 
2.4 Biochemical analysis 
Plasma glucose was measured using a glucose oxidase method (Yellow 
Springs glucose analyser, Yellow Springs Instrument Company, Yellow 
Springs, OH, USA). Plasma C-peptide concentrations were measured by an 
enzyme-linked immunosorbent assay using a commercial kit (Dako 
Diagnostics, Ely, UK). Standard laboratory methods were used to measure 
serum total cholesterol, HDL cholesterol, and triglyceride concentrations. 
Fibrinogen concentration was determined using an automated analyser by 
standard techniques (ACL 3000 Coagulometer, Instrumentation Laboratory, 
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Lexington, MA, USA). PAI-1 and E-selectin levels were measured by enzyme-
linked immunoassay kits (Innogenetics, Ghent, Belgium and R & D Systems, 
Minneapolis, MN, USA). Urinary albumin concentration was measured by 
radioimmunoassay [18] and the median AER used. 
DCCT-aligned HbA1c (non-diabetic < 6.1%) was determined by HPLC 
(Eurogenetics, Hampton, UK).  
2.5 Calculation of insulin secretion rates 
Estimation of insulin secretion rate (ISR) was carried out using a previously 
described purpose written programme [15] based on the two-compartment 
model of C-peptide kinetics developed by Polonsky and colleagues [14,17]. 
The two compartment model for C-peptide distribution is shown in Fig. 1 and 
is an indirect method of calculating ISR based on peripheral C-peptide 
concentrations. This is possible since C-peptide does not undergo first pass 
metabolism in the liver, is secreted in equimolar quantities to insulin and has a 
constant renal clearance. The model assumes that once secreted C-peptide 
distributes into a central intravascular compartment (Ct) consisting of the 
plasma space and tissues in rapid equilibration with plasma from which 
sampling occurs at time t, and a peripheral extravascular compartment at time 
t (Yt). Rate constants k1 and k2 describe the rate at which C-peptide passes 
from the plasma to the extravascular compartment (k1) and back again to the 
plasma compartment (k2). C-peptide is also irreversibly metabolized from the 
central compartment and excreted by the kidneys by another rate constant, 
k3. C-peptide kinetic parameters (k1 k2 k3 and the volume of distribution, VD 
were estimated based on previously published work [15,19]. It is assumed 
that plasma C-peptide decay follows a pattern that can be described by the 
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sum of two exponential decay curves. The half-lives for each known as the 
long half-life and the short half-life can be estimated in from age, sex, BMI and 
diabetic status. The volume of distribution of C-peptide is also necessary to 
model C-peptide decay and calculate the C-peptide kinetic parameters and is 
estimated from body surface area [20] and sex. C-peptide kinetic parameters 
were obtained for this population of study patients.  
Endogenous ISR at time t (St) can be calculated by solving differential 
equations for St (15). As part of that process it was necessary to model the 
concentration of C-peptide in the central compartment on a curve to allow 
manipulation of the function Ct  
ISR estimation and C-peptide modelling was performed with a purpose written 
programs using Microsoft Excel (Seattle, WA, USA). 
 
 
2.6 Statistical analysis 
The amount of insulin secreted over each 40-min time period at each glucose 
infusion rate was determined for unmodified human insulin and insulin aspart 
by calculating the area under the ISR curve using the trapezoid rule. Student’s 
t-test (paired) was used to test for differences in ISR between the two insulins 
using the Statistical Package for Social Science (SPSS, Chicago, IL, USA). 
For the various metabolic markers of vascular risk skewed data were 
normalized by logarithmic transformation and statistical comparison was by 
paired Student’s t-test using Graph Pad Instat (San Diego, CA, USA). Results 
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are expressed as mean ± SE for normally distributed data and median (range) 
for AER. Statistical significance was judged against a p value of 0.05.  
3. Results 
3.1 Patient disposition 
 
Twenty four people were originally recruited to this study. Two patients were 
withdrawn by the investigator prior to randomization because of concern 
about compliance. Of the 22 patients randomized a further patient was 
withdrawn by the investigator because of compliance issues and two patients 
withdrew due to changes in their personal circumstances. One patient had 
poor venous access and intravenous cannulation was not possible on one of 
the study days necessitating withdrawal. Eighteen patients therefore 
completed the study. 
 
 
 
3.2 Treatment periods 
Participants remained on insulin aspart for an average of 111 ± 31 days and 
on human insulin for an average of 107 ± 34 days (mean ± SD). The length of 
the treatment period between the two groups did not differ. 
3.3 Insulin doses 
The total dose of pre-meal insulin taken per day did not differ with insulin 
aspart compared to human soluble insulin (mean ± SD: 68.0 ± 8.2 vs 68.6 ± 
9.2 U/day). Likewise, the dose of bedtime NPH insulin given did not change 
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between the two periods (43.7 ± 5.0 vs 40.2 ± 3.9 U/day). No patient required 
a second dose of NPH insulin. 
3.4 Blood glucose control 
Glycated haemoglobin fell during the study (randomization vs insulin aspart vs 
human insulin (7.71 ± 0.13 vs 6.94 ± 0.12 vs 7.07 ± 0.13 %, both p<0.01). 
There was not a significant difference in HbA1c between insulin aspart and 
human insulin at the end of each treatment period. HbA1c improved from  
7.71 % at randomization to 6.89 % at the end of the first treatment period but 
had risen slightly to 7.12 % by the end of the second treatment period. There 
was thus an order effect between the first and second treatment periods. 
Self-monitored pre-breakfast blood glucose concentrations were comparable 
with insulin aspart and human insulin (7.0 ± 0.4 vs 6.5 ± 0.2 mmol/l, NS) 
(Fig.2). Post-prandial blood glucose concentrations 2 hours after breakfast 
tended to be lower with insulin aspart but this did not reach statistical 
significance (8.6 ± 0.7 vs 9.6 ± 0.5 mmol/l, p=0.074). After lunch and dinner 
post-prandial blood glucose concentrations were within the target range of 
5.0-7.5 mmol/l in both groups with no significant difference between the two 
pre-meal insulins. Although mean post-prandial blood glucose concentration 
after the three main meals of the day was at the upper end of the target range 
for insulin aspart and above target for human insulin this was not a statistically 
significant difference (7.5 ± 0.4 vs 8.2 ± 0.3 mmol/l, p=0.142). Before dinner 
blood glucose concentrations were lower with human insulin (6.6 ± 0.6 vs 5.4 
± 0.4 mmol/l, p=0.044) but before bed blood glucose values tended to be 
lower with insulin aspart (6.3 ± 0.4 vs 7.3 ± 0.3 mmol/l, p=0.058). 
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3.5 Biochemical outcome measures 
All measurements of biochemical outcome are shown in Table 2.  
There were no significant differences in pre-breakfast serum lipids, fibrinogen, 
E-selectin and AER following treatment with insulin aspart or human insulin. 
Concentrations of lipids, fibrinogen, E-selectin and AER did not change 
significantly between randomization and at the end of each treatment period 
on either insulin, in spite of the significant improvement in HbA1c. 
Levels of PAI-1 fell between randomization and following treatment with 
insulin aspart (97.7 ± 4.9 vs 86.8 ± 5.7 µg/l, p=0.044). There was no change 
in PAI-1 levels compared to baseline following treatment with human insulin 
(97.9 ± 4.9 vs 95.6 ± 5.3 µg/l). 
3.6 Insulin secretion rate 
The parameters VD, k1, k2, and k3 were estimated as (mean ± SD) 4.65 ± 0.44 
l, 0.061 ± 0.004, 0.048 ± 0.001, 0.059 ± 0.002 respectively for the insulin 
aspart group and 4.64 ± 0.44 l, 0.061 ± 0.003, 0.048 ± 0.0001, 0.058 ± 0.002 
for the unmodified human insulin group. Analysis of C-peptide parameters 
showed no significant differences between the two groups. 
Plasma glucose and plasma C-peptide concentrations during the stepped 
glucose infusion are shown in Fig. 3. 
Plasma glucose concentrations progressively rose and formed a plateau at 
each stage of the stepped glucose infusion. There was no difference in 
plasma glucose concentrations between the two groups at each step of the 
glucose infusion. 
 13 
Plasma C-peptide concentrations followed a similar pattern to plasma glucose 
concentrations tending to rise and plateau as glucose infusion rates 
progressively increased. Again plasma C-peptide concentrations did not vary 
between insulin aspart and human insulin at each stage of the stepped 
glucose infusion. 
The area under the curve (AUC) of the insulin secretion curve for each insulin 
is shown in Fig. 4. The AUC is equivalent to the amount of insulin secreted 
over each time period. There was no difference in total insulin secretion or 
insulin secretion at each stage of the stepped low-dose glucose infusion. Over 
the 160 min time period insulin secretion in those patients taking insulin aspart 
was 63.1 ± 9.0 nmol and 66.6 ± 9.1 nmol with human insulin (NS). 
4. Discussion 
The present study was of open-label design in contrast to our previous study 
[16]. The different pharmacokinetics and pharmacodynamics of insulin aspart 
and human insulin are well documented [21,22]. It was postulated that an 
open-label, as compared to a double-blind study, would allow target post-
prandial blood glucose concentrations to be achieved more easily in the 
insulin aspart group compared to the human insulin group since pre-meal 
insulin analogue doses could be increased to reduce post-prandial 
hyperglycaemia without the risk of between of late interprandial 
hypoglycaemia associated with human insulin. 
Target post-prandial blood glucose control was achieved in the insulin aspart 
group with a mean post-prandial blood glucose concentration of 7.5 mmol/l 
across the three main meals of the day. However, this was only 0.7 mmol/l 
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less than the mean post-prandial blood glucose concentration achieved with 
human insulin and was not a statistically significant difference. In fact, for two 
of the three meals of the day mean post-prandial blood glucose 
concentrations were in the target range with both insulin aspart and human 
insulin. Our studies have highlighted the difficulty in achieving a large 
difference in post-prandial blood glucose levels between the two groups when 
human soluble insulin is compared to a rapid-acting insulin analogue in 
people with good glucose control overall. In fact, our studies have somewhat 
surprisingly demonstrated that very good overall and post-prandial glycaemic 
control can be obtained in patients with insulin-treated Type 2 diabetes who 
are intensively managed using a pre-meal plus basal insulin regimen with 
frequent blood glucose monitoring and regular contact with a health care 
professional, regardless of whether human soluble insulin or a rapid-acting 
insulin analogue is used as pre-meal insulin therapy. This is pertinent since it 
is recognised that glycaemic variability, in addition to but independent of 
HbA1c, is a significant cause of oxidative stress in the development of diabetic 
complications ( ). Other studies have achieved greater differences in post-
prandial blood glucose control between human soluble insulin and rapid-
acting insulin analogues in Type 2 diabetes [10,11] but at notably worse levels 
of overall glycaemic control than was achieved in our studies. A comparison 
between NPH insulin alone and a rapid-acting insulin analogue in patients 
with insulin-treated Type 2 diabetes should cause a more marked difference 
in post-prandial blood glucose concentrations than could be achieved with the 
use of unmodified human insulin. 
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A greater difference in post-prandial blood glucose levels between the two 
arms of our studies would have more strongly tested the hypotheses of the 
studies. However, the use of surrogate markers do not always provide 
unequivocal answers to clinical questions and the evidence so far from our 
two studies and a further study in which lipid profile was examined [11] have 
yet to show any changes in markers of vascular risk associated with improved 
post-prandial glycaemic control. 
It is well recognised that an acute increase in blood glucose levels results in 
endothelial dysfunction in both normal and diabetic subjects (). In the present 
study E-selectin was measured as a marker of endothelial dysfunction and 
improved post-prandial glycaemic control was not associated with any change 
in E-selectin levels. In contrast Ceriello et al examined the effect of improved 
post-prandial blood glucose control on endothelial dysfunction in subjects with 
Type 2 diabetes by measuring flow-mediated dilation of the brachial artery (). 
In this study, there was greater preservation of flow-mediated dilation in the 
patients with Type 2 diabetes who had been given pre-prandial insulin aspart 
than those given unmodified human insulin. This study suggests that post-
prandial hyperglycaemia is accompanied endothelial dysfunction which can 
be modified by insulin aspart use in contrast to the present study. 
A large, prospective, long-term, randomized controlled trial looking at clinically 
useful patient orientated endpoints such as myocardial infarction, stroke or 
death is perhaps the only definitive way of establishing whether reducing post-
prandial blood glucose concentrations with rapid-acting insulin analogue use 
could be of real clinical benefit to patients. 
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At all stages of the low-dose stepped glucose infusion plasma glucose and C-
peptide levels were very similar in both groups and there was no difference in 
ISR. There are several possible reasons for this. Without achieving 
significantly improved post-prandial glycaemic control in the insulin aspart 
group, in comparison to human insulin, we were unable to fully test our 
original hypothesis.  
A second possibility is that participants could not increase their endogenous 
ISR enough for differences between the two different insulin treatments to be 
detectable. The UKPDS clearly showed that β-cell failure is progressive with 
50% of patients requiring insulin therapy 6 years after diagnosis increasing to 
80% after 9 years [23,24]. The mean duration of diabetes in our cohort of 
patients was over 13 years and all were insulin-treated implying that all had 
significant pancreatic failure with low levels of islet β-cell function and 
resultant low endogenous insulin secretion. It is possible that in our group of 
patients with longstanding Type 2 diabetes endogenous insulin secretion was 
too poor to be significantly augmented by subtle therapeutic changes. It would 
be interesting to repeat the present study using patients with Type 2 diabetes 
who have recently commenced insulin therapy since these patients have 
greater endogenous insulin reserve. 
Whilst no change in endogenous ISR was detected with insulin aspart therapy 
it may be that the improved blood glucose profile seen with rapid-acting 
insulin analogue use resulted in a reduction in exogenous insulin 
requirements. However, since HbA1c significantly improved during the study 
with an associated increase in exogenous insulin doses, it is not possible to 
test this hypothesis. 
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A possible criticism of this study is that participants were not supervised the 
night before insulin secretion measurement took place. Patients were asked 
to omit their night time dose of NPH and to fast for 12 h prior to attending the 
Investigation Unit at 0800 h the following morning. Preferably patients would 
have been admitted to the Investigation Unit the evening before each study 
day. Ideally an intravenous insulin infusion would have been used to lower 
fasting plasma glucose to similar levels in both groups and eliminate 
potentially confounding effects of differences in the basal glucose 
concentration prior to commencing the graded glucose infusion. However a 
previous study showed consistent measurement of ISR when basal plasma 
glucose levels were between 5-9 mmol/l regardless of whether insulin was 
given before the graded glucose infusion or not [14]. 
In summary, we were able to obtain good glycaemic control using an 
intensified pre-meal plus basal regimen with either insulin aspart or 
unmodified human insulin as pre-meal insulin. Insulin aspart has not been 
shown to have a consistent advantage in reducing markers of vascular risk or 
improving endogenous ISR compared to unmodified human insulin in our 
studies. 
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